BRPI0518096A - composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos - Google Patents
composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inosInfo
- Publication number
- BRPI0518096A BRPI0518096A BRPI0518096-1A BRPI0518096A BRPI0518096A BR PI0518096 A BRPI0518096 A BR PI0518096A BR PI0518096 A BRPI0518096 A BR PI0518096A BR PI0518096 A BRPI0518096 A BR PI0518096A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparation
- treatment
- medicament
- nitric oxide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 3
- 101100396994 Drosophila melanogaster Inos gene Proteins 0.000 title 1
- 230000005856 abnormality Effects 0.000 title 1
- 238000006471 dimerization reaction Methods 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 abstract 3
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 abstract 1
- CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63197104P | 2004-12-01 | 2004-12-01 | |
| US67200105P | 2005-04-14 | 2005-04-14 | |
| PCT/US2005/043190 WO2006060424A2 (en) | 2004-12-01 | 2005-11-28 | Inducible nitric oxide synthase dimerization inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0518096A true BRPI0518096A (pt) | 2008-10-28 |
Family
ID=36215758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0518096-1A BRPI0518096A (pt) | 2004-12-01 | 2005-11-28 | composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7825256B2 (enExample) |
| EP (1) | EP1817030A2 (enExample) |
| JP (1) | JP2008521908A (enExample) |
| KR (1) | KR20070084574A (enExample) |
| AR (1) | AR055287A1 (enExample) |
| AU (1) | AU2005311985A1 (enExample) |
| BR (1) | BRPI0518096A (enExample) |
| CA (1) | CA2589433A1 (enExample) |
| IL (1) | IL183392A0 (enExample) |
| TW (1) | TW200635587A (enExample) |
| WO (1) | WO2006060424A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070123572A1 (en) * | 2005-11-28 | 2007-05-31 | Kalypsys, Inc. | Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines |
| US20080293942A1 (en) * | 2005-11-28 | 2008-11-27 | Cousins Russell D | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives |
| CN101454317A (zh) * | 2005-11-28 | 2009-06-10 | 凯利普西斯公司 | 作为一氧化氮合酶二聚化抑制剂的咪唑衍生物 |
| FR2903405B1 (fr) * | 2006-07-04 | 2011-09-09 | Pasteur Institut | Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications |
| WO2008070447A2 (en) * | 2006-11-21 | 2008-06-12 | Smithkline Beecham Corporation | Anti-viral compounds |
| EP1939181A1 (en) * | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase |
| WO2008086176A2 (en) * | 2007-01-08 | 2008-07-17 | Kalypsys, Inc. | Topical pharmaceutical formulation comprising an inos inhibitor for the treatment of disease |
| JP2011510996A (ja) * | 2008-01-30 | 2011-04-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびその使用 |
| EP2240026A4 (en) * | 2008-01-30 | 2011-10-19 | Glaxosmithkline Llc | NEW SEE INHIBITORS AND THEIR USE |
| US8478446B2 (en) | 2008-06-13 | 2013-07-02 | Air Products And Chemicals, Inc. | Oxygen control system for oxygen enhanced combustion |
| US8578892B2 (en) * | 2008-06-13 | 2013-11-12 | Air Products And Chemicals, Inc. | Oxygen control system for oxygen enhanced combustion of solid fuels |
| JP2015180606A (ja) * | 2012-08-01 | 2015-10-15 | アステラス製薬株式会社 | 抗癌剤の併用による癌治療方法 |
| AU2015243537B2 (en) | 2014-04-08 | 2020-10-22 | The Methodist Hospital | INOS-inhibitory compositions and their use as breast cancer therapeutics |
| EP3166938A4 (en) | 2014-07-11 | 2018-01-17 | Northwestern University | 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase |
| JP6460382B2 (ja) * | 2014-11-28 | 2019-01-30 | 株式会社豊田自動織機 | 飽和ヘテロ環含有化合物、並びにこれを用いた二次電池用電極及び二次電池、結着剤、蛍光物質 |
| GB201512635D0 (en) | 2015-07-17 | 2015-08-26 | Ucl Business Plc | Uses of therapeutic compounds |
| WO2018152134A1 (en) | 2017-02-14 | 2018-08-23 | Research Triangle Institute | Proline-based neuropeptide ff receptor modulators |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1161237B (it) * | 1983-04-26 | 1987-03-18 | Montedison Spa | 1,4-dichetoni-insaturi ad attivita' fungicida |
| DE3433953A1 (de) * | 1984-09-15 | 1986-03-27 | A. Nattermann & Cie GmbH, 5000 Köln | Neue, eine imidazol-gruppe enthaltende 3,4-dihydro-2(1h)-pyridone und2(1h)-pyridone, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| US5795905A (en) | 1995-06-06 | 1998-08-18 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| DE19541146A1 (de) * | 1995-10-25 | 1997-04-30 | Schering Ag | Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren |
| US5874452A (en) | 1996-04-03 | 1999-02-23 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
| CA2619901A1 (en) | 1996-05-31 | 1997-12-04 | Allelix Neuroscience Inc. | Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
| DE19627310A1 (de) * | 1996-06-27 | 1998-01-02 | Schering Ag | Imidazolderivate als Stickstoffmonoxid-Synthase-Inhibitoren |
| DK0968206T3 (da) * | 1997-02-19 | 2007-03-26 | Berlex Inc | N-heterocykliske derivater som NOS-inhibitorer |
| US6432947B1 (en) * | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| ID23510A (id) * | 1997-06-27 | 2000-04-27 | Bp Chem Int Ltd | Proses polimerisasi |
| US6861448B2 (en) | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
| US20030191279A1 (en) | 1999-08-27 | 2003-10-09 | Goldstein Steven Wayne | Urea derivatives useful as anticancer agents |
| US6723743B1 (en) | 1999-09-28 | 2004-04-20 | Neurogen Corporation | High affinity small molecule C5a receptor modulators |
| YU23503A (sh) | 2000-09-29 | 2006-03-03 | Neurogen Corporation | Mali molekuli kao modulatori receptora c5a visokog afiniteta |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| FR2827286A1 (fr) | 2001-07-11 | 2003-01-17 | Aventis Cropscience Sa | Nouveaux composes fongicides |
| JP2006512280A (ja) | 2002-03-27 | 2006-04-13 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
| US20040014782A1 (en) | 2002-03-29 | 2004-01-22 | Krause James E. | Combination therapy for the treatment of diseases involving inflammatory components |
| CA2480888A1 (en) | 2002-03-29 | 2003-10-09 | Neurogen Corporation | New aryl imidazoles and related compounds as c5a receptor modulators |
| CN1894241A (zh) | 2002-08-09 | 2007-01-10 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑 |
| AU2003260033A1 (en) | 2002-08-29 | 2004-03-19 | Schering Aktiengesellschaft | Methods of treating acute respiratory distress syndrome |
| BRPI0406757A (pt) * | 2003-02-06 | 2005-12-20 | Basf Ag | Pirimidina, processo para preparar as mesmas, produto intermediário, agente pesticida, e, processo para combater fungos nocivos fitopatogênicos |
| CN101454317A (zh) * | 2005-11-28 | 2009-06-10 | 凯利普西斯公司 | 作为一氧化氮合酶二聚化抑制剂的咪唑衍生物 |
-
2005
- 2005-11-28 AR ARP050104970A patent/AR055287A1/es unknown
- 2005-11-28 BR BRPI0518096-1A patent/BRPI0518096A/pt not_active IP Right Cessation
- 2005-11-28 WO PCT/US2005/043190 patent/WO2006060424A2/en not_active Ceased
- 2005-11-28 JP JP2007544442A patent/JP2008521908A/ja active Pending
- 2005-11-28 KR KR1020077011898A patent/KR20070084574A/ko not_active Withdrawn
- 2005-11-28 AU AU2005311985A patent/AU2005311985A1/en not_active Abandoned
- 2005-11-28 TW TW094141754A patent/TW200635587A/zh unknown
- 2005-11-28 US US11/288,888 patent/US7825256B2/en not_active Expired - Fee Related
- 2005-11-28 EP EP05852447A patent/EP1817030A2/en not_active Withdrawn
- 2005-11-28 CA CA002589433A patent/CA2589433A1/en not_active Abandoned
-
2007
- 2007-05-24 IL IL183392A patent/IL183392A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20060116515A1 (en) | 2006-06-01 |
| TW200635587A (en) | 2006-10-16 |
| EP1817030A2 (en) | 2007-08-15 |
| AU2005311985A1 (en) | 2006-06-08 |
| US7825256B2 (en) | 2010-11-02 |
| CA2589433A1 (en) | 2006-06-08 |
| JP2008521908A (ja) | 2008-06-26 |
| IL183392A0 (en) | 2007-09-20 |
| WO2006060424A2 (en) | 2006-06-08 |
| AR055287A1 (es) | 2007-08-15 |
| KR20070084574A (ko) | 2007-08-24 |
| WO2006060424A3 (en) | 2007-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0518096A (pt) | composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos | |
| BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
| BRPI0510453A (pt) | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central | |
| BR0210711A (pt) | Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto | |
| BRPI0512075A (pt) | composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença | |
| CY1113269T1 (el) | Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων | |
| BRPI0417947A (pt) | composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
| BR112013011634A2 (pt) | derivados de 2,3-di-hidroimidazol[1,2-c]quinazolina substituídos por aminoálcool úteis para tratar os distúrbios hiperproliferativos e as doenças associadas com a angiogênese derivados de 2,3-di-hidroimidazol[1,2-c] | |
| BRPI0517619A (pt) | entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos | |
| BRPI0908353B8 (pt) | composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica | |
| BR0214553A (pt) | Compostos, processo de preparação, em fase lìquida, dos compostos, e, composições farmacêuticas | |
| BRPI0813244B8 (pt) | compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário | |
| BRPI0409109A (pt) | novos compostos | |
| NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
| BRPI0720742B8 (pt) | derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos | |
| BRPI0513858A (pt) | compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa | |
| BRPI0409241A (pt) | compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso | |
| BR112021023770A2 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BRPI0719920B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário | |
| BRPI0511722A (pt) | 3-amino-1-arilpropilindóis como inibidores da recaptação de monoamina | |
| BRPI0514310A (pt) | 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos | |
| BRPI0513744A (pt) | derivados de guanidina e usos terapêuticos dos mesmos | |
| BRPI0315958B8 (pt) | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 6A ANUIDADE. |